

DAFTAR PUSTAKA

- Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Delmas, C., Saillard, J., Dechanet, A., Fougerou, C., L  , M.-P., Peytavin, G., Mercier, N., Velou, P., Tubiana, S., Lescure, X., Faure, E., Nseir, S., ... Mentr  , F. (2022). Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial. *MedRxiv*.
<https://doi.org/10.1101/2022.03.30.22273206>
- Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., Ray, A. S., Cihlar, T., Siegel, D., Mackman, R. L., Clarke, M. O., Baric, R. S., & Denison, M. R. (2018). Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. *MBio*, 9(2). <https://doi.org/10.1128/mBio.00221-18>
- Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., ... Zarychanski, R. (2022). Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. *CMAJ : Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne*, 194(7), E242–E251. <https://doi.org/10.1503/cmaj.211698>
- Arch, B. N., Kovacs, D., Scott, J. T., Jones, A. P., Harrison, E. M., Rosala-Hallas, A., Gamble, C. G., Openshaw, P. J. M., Baillie, J. K., Semple, M. G., & Investigators, I. (2022). Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study. *MedRxiv*.
<https://doi.org/10.1101/2021.06.18.21259072>
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., ... Lane, H. C. (2020). Remdesivir for the Treatment of Covid-19 - Final Report. *The New England Journal of Medicine*, 383(19), 1813–1826.
<https://doi.org/10.1056/NEJMoa2007764>
- Burhan, E., Isbaniah, F., Susanto, A. D., Aditama, T. Y., Soedarono, Sartono, T. rahayu, Sugiri, Y. J., Rezki, T., Sinaga, B. Y., Handayani, R. R. D., & Agustin, H. (2020). *Pneumonia COVID-19: Diagnosis dan Penatalaksanaan di Indonesia*. Perhimpunan Dokter Paru Indonesia.
- Cennimo, D. J., Bergman, S. J., & Olsen, K. M. (2022). *Coronavirus Disease 2019 (COVID-19)*. Medscape. <https://emedicine.medscape.com/article/2500114-overview>
- D  rnemann, J., Burzio, C., Ronsse, A., Sprecher, A., de Clerck, H., van Herp, M., Koli  , M.-C., Yosifiva, V., Caluwaerts, S., McElroy, A. K., & Antierens, A. (2017). First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease. *The Journal of Infectious Diseases*, 215(2), 171–174. <https://doi.org/10.1093/infdis/jiw493>

- Endriani, E., & Rostinawati, T. (2020). REVIEW ARTIKEL : STRUKTUR, REPLIKASI DAN INHIBITOR RNA-DEPENDENT RNA POLYMERASE CORONAVIRUS. *Fakultas Farmasi, Universitas Padjadjaran, Vol 18, No.*
- Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *Journal of Biological Chemistry, 295(15)*, 4773–4779. <https://doi.org/https://doi.org/10.1074/jbc.AC120.013056>
- Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. H., Osinusi, A., Chen, S., ... Hill, J. A. (2022). Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *The New England Journal of Medicine, 386(4)*, 305–315. <https://doi.org/10.1056/NEJMoa2116846>
- Hong, Y.-N., Xu, J., Sasa, G. B. K., Zhou, K.-X., & Ding, X.-F. (2021). Remdesivir as a broad-spectrum antiviral drug against COVID-19. *European Review for Medical and Pharmacological Sciences, 25(1)*, 541–548. https://doi.org/10.26355/eurrev_202101_24426
- Hosseini, H., Sadeghi, A., Tabarsi, P., Etemadimanesh, A., Darazam, I. A., Aghdami, N., Kalantari, S., Hasibi, M., Hadadi, A., Babamahmoodi, F., Momen-Heravi, M., Hormati, A., Panahi, Y., Khodashahi, R., & Salehi, M. (2021). Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial. *MedRxiv*. <https://doi.org/10.1101/2021.08.13.21261992>
- Jacobs, M., Rodger, A., Bell, D. J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R. J., Hopkins, S., Hughes, J., Jabeen, F., Johannessen, I., Karageorgopoulos, D., Lackenby, A., Lester, R., Liu, R. S. N., MacConnachie, A., Mahungu, T., Martin, D., Marshall, N., ... Thomson, E. C. (2016). Late Ebola virus relapse causing meningoencephalitis: a case report. *The Lancet, 388(10043)*, 498–503. [https://doi.org/https://doi.org/10.1016/S0140-6736\(16\)30386-5](https://doi.org/https://doi.org/10.1016/S0140-6736(16)30386-5)
- Khanal, P. (2020). Remdesivir for COVID-19 Treatment: Mechanism of Action, Synthesis, and Clinical Trials. *WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 9*, 1062–1068. <https://doi.org/10.20959/wjpps20208-16808>
- Krnic Martinic, M., Pieper, D., Glatt, A., & Puljak, L. (2019). Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks. *BMC Medical Research Methodology, 19(1)*, 203. <https://doi.org/10.1186/s12874-019-0855-0>
- Lamb, Y. N. (2020). Remdesivir: First Approval. *Drugs, 80(13)*, 1355–1363. <https://doi.org/10.1007/s40265-020-01378-w>
- Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis, 10(2)*, 102–108. <https://doi.org/https://doi.org/10.1016/j.jpha.2020.03.001>

- Lukito, J. I. (2020). Tinjauan Antivirus Untuk Terapi COVID-19. *CDKjournal*, 47 no, 340–345.
- Malik, M. I., Zafar, S. A. F., Malik, M., Qayyum, F., Akram, I., Arshad, A., Waheed, K., Saleem, J., Jabbar, A., Tahir, M. J., & Yousaf, Z. (2022). The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country. *Exploratory Research in Clinical and Social Pharmacy*, 5, 100107.
<https://doi.org/https://doi.org/10.1016/j.rcsop.2022.100107>
- Mehta, R. M., Bansal, S., Bysani, S., & Kalpakam, H. (2020). A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. *MedRxiv*.
<https://doi.org/10.1101/2020.11.05.20226373>
- Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*, 4(1), 1.
<https://doi.org/10.1186/2046-4053-4-1>
- Mulangu, S., Dodd, L. E., Davey, R. T. J., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., Ali, R., Coulibaly, S., Levine, A. C., Grais, R., Diaz, J., Lane, H. C., Muyembe-Tamfum, J.-J., Sivahera, B., Camara, M., ... Nordwall, J. (2019). A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. *The New England Journal of Medicine*, 381(24), 2293–2303.
<https://doi.org/10.1056/NEJMoa1910993>
- Naveed, M., Uddin, S., Khan, M. K., & Khan, Z. (2021). Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy. In *Journal of pharmacy practice* (Vol. 34, Issue 3, pp. 343–346).
<https://doi.org/10.1177/0897190021997001>
- Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020). The journey of remdesivir: From Ebola to COVID-19. *Drugs in Context*, 9. <https://doi.org/10.7573/DIC.2020-4-14>
- Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., & Tian, D.-S. (2020). Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases*, 71(15), 762–768.
<https://doi.org/10.1093/cid/ciaa248>
- Rezagholizadeh, A., Khiali, S., Sarbakhsh, P., & Entezari-Maleki, T. (2021). Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. *European Journal of Pharmacology*, 897, 173926.
<https://doi.org/https://doi.org/10.1016/j.ejphar.2021.173926>
- Russo, A., Binetti, E., Borrazzo, C., Cacciola, E. G., Battistini, L., Ceccarelli, G., Mastroianni, C. M., & d\textquoterightEttore, G. (2021). Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. *MedRxiv*.
<https://doi.org/10.1101/2021.07.01.21259852>

- Santenna, C., Vidyasagar, K., Amarneni, K. C., Ghanta, S. N., Sadasivam, B., Pathan, S., & Padmavathi, R. (2021). The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. *Therapeutic Advances in Drug Safety*, 12, 20420986211042516. <https://doi.org/10.1177/20420986211042517>
- Susilo, A., Jasirwan, C., Wafa, S., Maria, S., Rajabto, W., Muradi, A., Fachriza, I., Putri, M. Z., & Gabriella, S. (2022). Mutasi dan Varian Coronavirus Disease 2019 (COVID-19): Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, Vol. 9, No, 59–81.
- Susilo, A., Rumende, C., Pitoyo, C., Santoso, W., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E., Chen, L., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C., & Yuniastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, 7, 45. <https://doi.org/10.7454/jpdi.v7i1.415>
- Tsuzuki, S., Hayakawa, K., Uemura, Y., Shinozaki, T., Matsunaga, N., Terada, M., Suzuki, S., Ohtsu, H., Asai, Y., Kitajima, K., Saito, S., Yamada, G., Shibata, T., Kondo, M., Izumi, K., Hojo, M., Mizoue, T., Yokota, K., Nakamura-Uchiyama, F., ... Ohmagari, N. (2021). Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan. *MedRxiv*. <https://doi.org/10.1101/2021.03.09.21253183>
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. In *Cell research* (Vol. 30, Issue 3, pp. 269–271). <https://doi.org/10.1038/s41422-020-0282-0>
- Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., ... Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet (London, England)*, 395(10236), 1569–1578. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9)
- Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., Larson, N., Strickley, R., Wells, J., Stuthman, K. S., van Tongeren, S. A., Garza, N. L., Donnelly, G., Shurtleff, A. C., Retterer, C. J., ... Bavari, S. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*, 531(7594), 381–385. <https://doi.org/10.1038/nature17180>